Intravitreal ranibizumab for the treatment of cystoid macular edema in central retinal vein occlusion with good visual acuity by PRN, phase 2 trial.

Intravitreal ranibizumab for the treatment of cystoid macular edema in central retinal vein occlusion with good visual acuity by PRN, phase 2 trial. - Intravitreal ranibizumab for the treatment of cystoid macular edema in central retinal vein occlusion by PRN.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015826

Enrollment

Registered

2014-12-03

Start date

2014-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal vein occlusion

Interventions

Ranibizumab 0.5 mg/0.05 ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Study eye Snellen equivalent BCVA of 20/20 to 20/400. Mean central subfoveal thickness over 0.250mm.

Exclusion criteria

Exclusion criteria: Juvenile central retinal vein occlusion. Hemi central retinal vein occlusion. History of cerebral infarction or myocardial infarction. History of vitrectomy. History or presence of age-related macular degeneration or diabetic retinopathy. Previous use of subtenon injection of corticosteroids, intravitreal injection of anti-VEGF drugs or panretinal photocoaguration within 4 months.

Design outcomes

Primary

Measure	Time frame
ETDRS chart and the change from the baseline at 12 months after injection.	—

Countries

Japan

Contacts

Public ContactAyumu Manabe

Nihon universty hospital Department of ophthalmology

ayumu.m76@gmail.com0332931711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026